British cost agency to take broader view of drug value
LONDON (Reuters) - British healthcare cost agency NICE is to take a broader view of the value offered by new medicines under proposals that may make it more likely that...
All Stories
Novartis CEO reshapes drugmaker for ‘brutal’ new world
BASEL, Switzerland (Reuters) - Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be...
GSK cancer vaccine fails again but testing continues
(Reuters) - An experimental cancer vaccine from GlaxoSmithKline has failed in a second test - this time against lung cancer - but the British company said it still hoped to...
Indian quality woes point to generic drugs shake-out: Novartis
BASEL, Switzerland (Reuters) - Recent manufacturing problems in India suggest some makers of generic drugs will struggle to compete in the face of a rising quality bar, pointing to a...
GSK cancer vaccine fails again but testing continues
(Reuters) - An experimental cancer vaccine from GlaxoSmithKline has failed in a second test - this time against lung cancer - but the British company said it still hoped to...
Novartis CEO reshapes drugmaker for ‘brutal’ new world
BASEL, Switzerland (Reuters) - Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be...
Rivals race to develop new biotech asthma drugs
LONDON (Reuters) - Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new...
Rivals race to develop new biotech asthma drugs
LONDON (Reuters) - Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new...
More firms weigh IPOs as biotech fever reaches Europe
LONDON/ZURICH (Reuters) - Biotech fever is spreading to Europe from the United States with a successful stock market debut for a cat allergy company in Britain seen as a bellwether...
India’s Lupin seeks biosimilar, lung drug partners
MUMBAI (Reuters) - Indian drugmaker Lupin Ltd is seeking new partnership agreements as it moves into the promising fields of inhaled lung drugs and copies of biotechnology drugs, its managing...